BACTROBAN® Cream
(mupirocin calcium cream, 2%)
For Dermatologic Use

DESCRIPTION
BACTROBAN Cream (mupirocin calcium cream, 2%) contains the dihydrate crystalline
calium hemi-salt of the antibiotic mupirocin. Chemically, it is (αE,2S,3R,4R,5S)-5-
[(2S,3S,4S,5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-β-methyl-2H-
pyran-2-crotonic acid, ester with 9-hydroxynonanoic acid, calcium salt (2:1), dihydrate.
The molecular formula of mupirocin calcium is (C26H43O9)2Ca•2H2O, and the molecular
weight is 1075.3. The molecular weight of mupirocin free acid is 500.6. The structural formula
of mupirocin calcium is:

BACTROBAN Cream is a white cream that contains 2.15% w/w mupirocin calcium
(equivalent to 2.0% mupirocin free acid) in an oil and water-based emulsion. The inactive
ingredients are benzyl alcohol, cetomacrogol 1000, cetyl alcohol, mineral oil, phenoxyethanol,
purified water, stearyl alcohol, and xanthan gum.

CLINICAL PHARMACOLOGY
Pharmacokinetics: Systemic absorption of mupirocin through intact human skin is minimal.
The systemic absorption of mupirocin was studied following application of BACTROBAN
Cream 3 times daily for 5 days to various skin lesions (>10 cm in length or 100 cm² in area) in
16 adults (aged 29 to 60 years) and 10 children (aged 3 to 12 years). Some systemic absorption
was observed as evidenced by the detection of the metabolite, monic acid, in urine. Data from
this trial indicated more frequent occurrence of percutaneous absorption in children (90% of
subjects) compared with adults (44% of subjects); however, the observed urinary concentrations
in children (0.07 to 1.3 mcg/mL [1 pediatric subject had no detectable level]) are within the
observed range (0.08 to 10.03 mcg/mL [9 adults had no detectable level]) in the adult population.
In general, the degree of percutaneous absorption following multiple dosing appears to be
minimal in adults and children. Any mupirocin reaching the systemic circulation is rapidly
metabolized, predominantly to inactive monic acid, which is eliminated by renal excretion.
Microbiology: Mupirocin is an antibacterial agent produced by fermentation using the
organism Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by reversibly
and specifically binding to bacterial isoleucyl transfer-RNA (tRNA) synthetase. Due to this unique mode of action, mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents.

When mupirocin resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC >512 mcg/mL) has been reported in increasing numbers of isolates of *Staphylococcus aureus* and with higher frequency in coagulase-negative staphylococci. Mupirocin resistance occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci. Because of the occurrence of mupirocin resistance in methicillin-resistant *Staphylococcus aureus* (MRSA), it is appropriate to test MRSA populations for mupirocin susceptibility prior to the use of mupirocin using a standardized method.\(^{1,2,3}\)

Mupirocin is bactericidal at concentrations achieved by topical application. Mupirocin is highly protein bound (>97%), and the effect of wound secretions on the MICs of mupirocin has not been determined.

Mupirocin has been shown to be active against susceptible strains of *S. aureus* and *Streptococcus pyogenes*, both in vitro and in clinical trials (see INDICATIONS AND USAGE). The following in vitro data are available, **but their clinical significance is unknown**. Mupirocin is active against most isolates of *Staphylococcus epidermidis*.

### INDICATIONS AND USAGE

BACTROBAN Cream is indicated for the treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm\(^2\) in area) due to susceptible strains of *S. aureus* and *S. pyogenes*.

### CONTRAINDICATIONS

BACTROBAN Cream is contraindicated in patients with known hypersensitivity to any of the constituents of the product.

### WARNINGS

Avoid contact with the eyes. In case of accidental contact, rinse well with water.

In the event of a sensitization or severe local irritation from BACTROBAN Cream, usage should be discontinued, and appropriate alternative therapy for the infection instituted.

*Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including BACTROBAN, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

*C. difficile* produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing isolates of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful
medical history is necessary since CDAD has been reported to occur over 2 months after the
administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against
*C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein
supplementation, antibacterial treatment of *C. difficile*, and surgical evaluation should be
instituted as clinically indicated.

**PRECAUTIONS**

**General:** As with other antibacterial products, prolonged use may result in overgrowth of
nonsusceptible microorganisms, including fungi (see DOSAGE AND ADMINISTRATION).

BACTROBAN Cream is not formulated for use on mucosal surfaces.

**Information for Patients:**

- Use this medication only as directed by the healthcare provider. It is for external use only.
  Avoid contact with the eyes. If BACTROBAN Cream gets in or near the eyes, rinse
  thoroughly with water.
- The treated area may be covered by gauze dressing if desired.
- Report to the healthcare provider any signs of local adverse reactions. The medication should
  be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs.
- If no improvement is seen in 3 to 5 days, contact the healthcare provider.

**Drug Interactions:** The effect of the concurrent application of topical mupirocin calcium
cream and other topical products has not been studied.

**Carcinogenesis, Mutagenesis, Impairment of Fertility:** Long-term studies in animals to
evaluate carcinogenic potential of mupirocin calcium have not been conducted.

Fertility studies were performed in rats with mupirocin administered subcutaneously at doses
up to 49 times a human topical dose of 1 gram/day (approximately 20 mg mupirocin per day) on
a mg/m² basis and revealed no evidence of impaired fertility from mupirocin sodium.

**Pregnancy:** Teratogenic Effects: Pregnancy Category B. Teratology studies have been
performed in rats and rabbits with mupirocin administered subcutaneously at doses up to 78 and
154 times, respectively, a human topical dose of 1 gram/day (approximately 20 mg mupirocin
per day) on a mg/m² basis and revealed no evidence of harm to the fetus due to mupirocin. There
are, however, no adequate and well-controlled studies in pregnant women. Because animal
reproduction studies are not always predictive of human response, this drug should be used
during pregnancy only if clearly needed.
**Nursing Mothers:** It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when BACTROBAN Cream is administered to a nursing woman.

**Pediatric Use:** The safety and effectiveness of BACTROBAN Cream have been established in the age groups 3 months to 16 years. Use of BACTROBAN Cream in these age groups is supported by evidence from adequate and well-controlled trials of BACTROBAN Cream in adults with additional data from 93 pediatric subjects studied as part of the pivotal trials in adults (see CLINICAL STUDIES).

**Geriatric Use:** In 2 well-controlled trials, 30 subjects older than 65 years were treated with BACTROBAN Cream. No overall difference in the efficacy or safety of BACTROBAN Cream was observed in this patient population when compared with that observed in younger patients.

**ADVERSE REACTIONS**

In 2 randomized, double-blind, double-dummy trials, 339 subjects were treated with topical BACTROBAN Cream plus oral placebo. Adverse events thought to be possibly or probably drug-related occurred in 28 (8.3%) subjects. The incidence of those events that were reported in at least 1% of subjects enrolled in these trials were: headache (1.7%), rash, and nausea (1.1% each).

Other adverse events thought to be possibly or probably drug-related which occurred in less than 1% of subjects were: abdominal pain, burning at application site, cellulitis, dermatitis, dizziness, pruritus, secondary wound infection, and ulcerative stomatitis.

In a supportive trial in the treatment of secondarily infected eczema, 82 subjects were treated with BACTROBAN Cream. The incidence of adverse events thought to be possibly or probably drug-related was as follows: nausea (4.9%), headache, and burning at application site (3.6% each), pruritus (2.4%) and 1 report each of abdominal pain, bleeding secondary to eczema, pain secondary to eczema, hives, dry skin, and rash.

Systemic allergic reactions, including anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with formulations of BACTROBAN.

**OVERDOSAGE**

Intravenous infusions of 252 mg, as well as single oral doses of 500 mg of mupirocin, have been well tolerated in healthy adult subjects. There is no information regarding overdose of BACTROBAN Cream.

**DOSAGE AND ADMINISTRATION**

A small amount of BACTROBAN Cream should be applied to the affected area 3 times daily for 10 days. The area treated may be covered with gauze dressing if desired. Patients not showing a clinical response within 3 to 5 days should be re-evaluated.
CLINICAL STUDIES

The efficacy of topical BACTROBAN Cream for the treatment of secondarily infected traumatic skin lesions (e.g., lacerations, sutured wounds, and abrasions not more than 10 cm in length or 100 cm² in total area) was compared with that of oral cephalexin in 2 randomized, double-blind, double-dummy clinical trials. Clinical efficacy rates at follow-up in the per-protocol populations (adults and pediatric subjects included) were 96.1% for BACTROBAN Cream (n = 231) and 93.1% for oral cephalexin (n = 219). Pathogen eradication rates at follow-up in the per-protocol populations were 100% for both BACTROBAN Cream and oral cephalexin.

**Pediatrics:** There were 93 pediatric subjects aged 2 weeks to 16 years enrolled per protocol in the secondarily infected skin lesion trials, although only 3 were less than 2 years of age in the population treated with BACTROBAN Cream. Subjects were randomized to either 10 days of topical BACTROBAN Cream 3 times daily or 10 days of oral cephalexin (250 mg 4 times daily for subjects >40 kg or 25 mg/kg/day oral suspension in 4 divided doses for subjects ≤40 kg). Clinical efficacy at follow-up (7 to 12 days post-therapy) in the per-protocol populations was 97.7% (43/44) for BACTROBAN Cream and 93.9% (46/49) for cephalexin. Only 1 adverse event (headache) was thought to be possibly or probably related to drug therapy with BACTROBAN Cream in the intent-to-treat pediatric population of 70 children (1.4%).

HOW SUPPLIED

BACTROBAN Cream is supplied in 15-gram and 30-gram tubes.

NDC 0029-1527-22 (15-gram tube)
NDC 0029-1527-25 (30-gram tube)

Store at or below 25°C (77°F). Do not freeze.

REFERENCES


